CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.

ABSTRACT:

Introduction

We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort.

Methods

Cutoffs for Elecsys amyloid-β_1-42 (Aβ), total tau/Aβ(1-42), and phosphorylated tau/Aβ(1-42) were defined against [¹⁸F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [¹⁸F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied.

Results

CSF total tau/Aβ(1-42) and phosphorylated tau/Aβ(1-42) ratios were highly concordant with PET classification in BioFINDER (ov

SUBMITTER: Hansson O 

PROVIDER: S-EPMC6119541 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature